Shanghai-based Everest Medicines Limited raised US$ 310 million in a Series C round. The company is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia. According to the press release, “The US$ 310 million Series C financing […]
